Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights From Real‐World Practice

Oncologist - United States
doi 10.1634/theoncologist.2019-0039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Checkpoint Inhibitor Pneumonitis — Real-World Incidence and Risk

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination VEGFR/immune Checkpoint Inhibitor Therapy: A Promising New Treatment for Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2018English

Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?

Oncologist
Cancer ResearchMedicineOncology
2015English

T-Cell Lymphoma Secondary to Checkpoint Inhibitor Therapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Trends in the Utilization of Imaging for Upper Tract Urothelial Carcinoma

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2016English

Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy

Clinical Genitourinary Cancer
OncologyUrology
2015English

Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy